Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, FiscalAI reports.
Theriva Biologics Stock Performance
Shares of TOVX stock traded down $0.01 during trading hours on Friday, hitting $0.15. 326,814 shares of the company were exchanged, compared to its average volume of 10,212,197. The firm has a fifty day simple moving average of $0.21 and a 200 day simple moving average of $0.24. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 0.13. Theriva Biologics has a 52-week low of $0.14 and a 52-week high of $0.49. The stock has a market capitalization of $5.03 million, a price-to-earnings ratio of -0.00 and a beta of 1.27.
Theriva Biologics Company Profile
Theriva Biologics, Inc. is a clinical-stage biotechnology company developing treatments based on microbiome science and cancer immunotherapy. The company focuses on therapeutics intended to address serious diseases with limited treatment options, including cancer and conditions associated with disruption of the intestinal microbiome. Its lead candidate, VCN-01, is a genetically engineered oncolytic adenovirus designed to selectively replicate in and destroy tumor cells while stimulating an immune response against cancer.
Read More
- Five stocks we like better than Theriva Biologics
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
